<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85659">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01897350</url>
  </required_header>
  <id_info>
    <org_study_id>Study 1953</org_study_id>
    <nct_id>NCT01897350</nct_id>
  </id_info>
  <brief_title>Myocardial Oedema in ST Segment Elevation Myocardial Infarction Myocardial</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elisa McAlindon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bristol</source>
  <oversight_info>
    <authority>United Kingdom: National Research Ethics Service</authority>
    <authority>United Kingdom: National Health Service</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac magnetic resonance imaging (CMR) is a non invasive technique used to obtain
      functional and anatomical information on the heart.  Several CMR parameters measured after
      primary percutaneous coronary intervention (PPCI) have been shown to have prognostic value
      and are increasingly being used as surrogate endpoints in clinical trials. Myocardial oedema
      is a prognostic indicator following myocardial infarction1. Myocardial salvage is calculated
      as the myocardial oedema minus infarct size; this again is a prognostic indicator following
      STEMI. However, myocardial oedema imaging is controversial. There are multiple sequences
      available, with no standardisation of sequences used to assess this surrogate endpoint. The
      investigators propose to conduct a study to measure the myocardial oedema by all available
      techniques to determine the agreement between these methods.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The mass of myocardial oedema measured by CMR</measure>
    <time_frame>Day 2 following STEMI</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extra cellular volume</measure>
    <time_frame>Day 2 following STEMI</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>ST Segment Elevation Myocardial Infarction</condition>
  <condition>Myocardial Oedema</condition>
  <arm_group>
    <arm_group_label>CMR following ST segment myocardial infarction</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac magnetic resonance imaging</intervention_name>
    <arm_group_label>CMR following ST segment myocardial infarction</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        30 patients will be undergo a CMR scan day 2 following STEMI
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  STEMI

          -  providing written informed consent

        Exclusion Criteria:

          -  contraindication to CMR,

          -  atrial fibrillation,

          -  claustrophobia,

          -  eGFR &lt; 30
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elisa McAlindon, BMBS</last_name>
    <phone>+441173425888</phone>
    <email>elisa.mcalindon@bristol.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bristol Heart Institute</name>
      <address>
        <city>Bristol</city>
        <state>Avon</state>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisa McAlindon, BMBS</last_name>
      <phone>+441173425888</phone>
      <email>elisa.mcalindon@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Elisa McAlindon, BMBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 11, 2013</lastchanged_date>
  <firstreceived_date>July 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Bristol</investigator_affiliation>
    <investigator_full_name>Elisa McAlindon</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>Myocardial edema</keyword>
  <keyword>Cardiovascular magnetic resonance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
